Editor’s note: Daniel S. Fitzgerald is CEO of Apollo Intelligence, the parent company to research firms InCrowd and SurveyHealthcareGlobus. 

The pandemic has accelerated tech innovations and adoption in most industries. For life sciences this has meant major breakthroughs, not the least of which was the development and global delivery of COVID-19 vaccines in record time. Accelerated adoption of health care technologies such as telehealth and remote patient monitoring, and creative approaches to safe health care delivery born from pandemic shortages, are providing lasting benefits to both clinician and patient. 

These health care innovations were envisioned with the understanding that time is our most precious asset and resource in fighting an aggressive, little understood, deadly virus. To address the life science pandemic demands, multiple sectors across the entire industry needed to step up, and they did. 

Market research didn’t stand still, either. Life science organizations rely heavily on the voice of the clinician, and clinicians in turn see insights survey participation as an important way to amplify their voice. A year or more into the pandemic, the entities that rely heavily on market research began to realize that the traditional pace and approach of market learning to inform business decisioning is insufficient and increasingly becoming stale. 

Though it began pre-pandemic, the need for advanced technology and process to springboard creativity and innovation has never been more apparent – with continuous on-demand research and rapid-learning a business imperative. 

In life sciences, 2022 will bring a further push toward tech innovation and new paths to customer access and engagement, particularly in market insights as it forms the foundation of faster, continuous learning. 

After fielding more than a million questions to health care professionals during the two ye...